Cinclus Pharma Holding AB (publ) (CINPHA.ST)
- Previous Close
9.60 - Open
9.69 - Bid 9.70 x --
- Ask 9.80 x --
- Day's Range
9.50 - 9.80 - 52 Week Range
9.31 - 40.00 - Volume
23,374 - Avg. Volume
72,189 - Market Cap (intraday)
456.07M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-4.54 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.67
Cinclus Pharma Holding AB (publ), a clinical stage pharmaceutical company, engages in the development of the drug candidate for the treatment of related diseases. Its lead product is linaprazan glurate for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer bacteria Helicobacter pylori (H. pylori). The company was founded in 2014 and is based in Stockholm, Sweden.
www.cincluspharma.com18
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CINPHA.ST
View MorePerformance Overview: CINPHA.ST
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CINPHA.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CINPHA.ST
View MoreValuation Measures
Market Cap
456.07M
Enterprise Value
-110.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
79.30
Price/Book (mrq)
0.82
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.36%
Return on Equity (ttm)
-70.23%
Revenue (ttm)
4.58M
Net Income Avi to Common (ttm)
-168.03M
Diluted EPS (ttm)
-4.54
Balance Sheet and Cash Flow
Total Cash (mrq)
566.72M
Total Debt/Equity (mrq)
0.05%
Levered Free Cash Flow (ttm)
-122.47M